Immunotherapy plus chemo before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (squamous cell carcinoma) that has spread to lymph nodes but not to distant parts of the body.
- Your cancer is in the lip, mouth, throat, voice box, or nearby areas.
- You are generally well enough to carry out daily activities (ECOG score 0 or 1).
- You have not had prior cancer treatment for this condition, including surgery, radiation, or chemotherapy.
- You do not have active autoimmune diseases or conditions that require strong immune-suppressing medications.
- You have adequate kidney, liver, and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.